222 related articles for article (PubMed ID: 33658534)
1. Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men.
van den Hoek AM; Verschuren L; Caspers MPM; Worms N; Menke AL; Princen HMG
Sci Rep; 2021 Mar; 11(1):5050. PubMed ID: 33658534
[TBL] [Abstract][Full Text] [Related]
2. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
3. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
4. Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters.
Briand F; Maupoint J; Brousseau E; Breyner N; Bouchet M; Costard C; Leste-Lasserre T; Petitjean M; Chen L; Chabrat A; Richard V; Burcelin R; Dubroca C; Sulpice T
Metabolism; 2021 Apr; 117():154707. PubMed ID: 33444606
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery.
Boeckmans J; Gatzios A; Heymans A; Rombaut M; Rogiers V; De Kock J; Vanhaecke T; Rodrigues RM
Cells; 2022 Mar; 11(5):. PubMed ID: 35269515
[TBL] [Abstract][Full Text] [Related]
6. Investigating fibrosis and inflammation in an ex vivo NASH murine model.
Gore E; Bigaeva E; Oldenburger A; Jansen YJM; Schuppan D; Boersema M; Rippmann JF; Broermann A; Olinga P
Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G336-G351. PubMed ID: 31905025
[TBL] [Abstract][Full Text] [Related]
7. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.
Baandrup Kristiansen MN; Veidal SS; Christoffersen C; Feigh M; Vrang N; Roth JD; Erickson M; Adorini L; Jelsing J
BMC Gastroenterol; 2019 Dec; 19(1):228. PubMed ID: 31883514
[TBL] [Abstract][Full Text] [Related]
8. A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology.
van den Hoek AM; Verschuren L; Worms N; van Nieuwkoop A; de Ruiter C; Attema J; Menke AL; Caspers MPM; Radhakrishnan S; Salic K; Kleemann R
Cells; 2020 Sep; 9(9):. PubMed ID: 32883049
[TBL] [Abstract][Full Text] [Related]
9. A 3-week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death.
Briand F; Heymes C; Bonada L; Angles T; Charpentier J; Branchereau M; Brousseau E; Quinsat M; Fazilleau N; Burcelin R; Sulpice T
Clin Transl Sci; 2020 May; 13(3):529-538. PubMed ID: 31981449
[TBL] [Abstract][Full Text] [Related]
10. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
[No Abstract] [Full Text] [Related]
11. Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes.
Liang W; Verschuren L; Mulder P; van der Hoorn JW; Verheij J; van Dam AD; Boon MR; Princen HM; Havekes LM; Kleemann R; van den Hoek AM
Br J Pharmacol; 2015 Nov; 172(22):5293-305. PubMed ID: 26292849
[TBL] [Abstract][Full Text] [Related]
12. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
[TBL] [Abstract][Full Text] [Related]
13. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis.
Perakakis N; Stefanakis K; Feigh M; Veidal SS; Mantzoros CS
Liver Int; 2021 Aug; 41(8):1853-1866. PubMed ID: 33788377
[TBL] [Abstract][Full Text] [Related]
14. Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH.
Boeckmans J; Buyl K; Natale A; Vandenbempt V; Branson S; De Boe V; Rogiers V; De Kock J; Rodrigues RM; Vanhaecke T
Pharmacol Res; 2019 Jun; 144():377-389. PubMed ID: 31028903
[TBL] [Abstract][Full Text] [Related]
15. Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice.
Tsai HC; Chang FP; Li TH; Liu CW; Huang CC; Huang SF; Yang YY; Lee KC; Hsieh YC; Wang YW; Lee TY; Huang YH; Hou MC; Lin HC
Biomed Res Int; 2019; 2019():6740616. PubMed ID: 31321239
[TBL] [Abstract][Full Text] [Related]
16. The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model.
Liu L; Liu C; Zhao M; Zhang Q; Lu Y; Liu P; Yang H; Yang J; Chen X; Yao Y
PLoS One; 2020; 15(12):e0243911. PubMed ID: 33326461
[TBL] [Abstract][Full Text] [Related]
17. A novel hamster nonalcoholic steatohepatitis model induced by a high-fat and high-cholesterol diet.
Miyaoka Y; Jin D; Tashiro K; Masubuchi S; Ozeki M; Hirokawa F; Hayashi M; Takai S; Uchiyama K
Exp Anim; 2018 May; 67(2):239-247. PubMed ID: 29311502
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
[TBL] [Abstract][Full Text] [Related]
19. Molecular drivers of non-alcoholic steatohepatitis are sustained in mild-to-late fibrosis progression in a guinea pig model.
Ipsen DH; Skat-Rørdam J; Tsamouri MM; Latta M; Lykkesfeldt J; Tveden-Nyborg P
Mol Genet Genomics; 2019 Jun; 294(3):649-661. PubMed ID: 30759275
[TBL] [Abstract][Full Text] [Related]
20. An Open Label, Randomized, Multicenter Study of Elafibranor in Children With Nonalcoholic Steatohepatitis.
Goyal NP; Mencin A; Newton KP; Durelle J; Carrier C; Ugalde-Nicalo P; Noel B; Mouton J; Vargas D; Magrez D; Tadde B; Birman P; Best BM; Addy C; Schwimmer JB
J Pediatr Gastroenterol Nutr; 2023 Aug; 77(2):160-165. PubMed ID: 37084342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]